As a key regulator of expression of FASN and other enzymes in fatty acid synthesis, SCD, LDLR, and HMG-CoA reductase, SREBP1c and SREBP2 are potential targets for cancer therapy, and betulin and fatostatin have been proposed as SREBP inhibitors. Here, HMGCR is linked to cancer.